How to Identify Cardiac Amyloidosis Patients Who Might Benefit From Cardiac Transplantation.

Competing Interests: Funding Support and Author Disclosures Dr Fontana has received consulting income from Eidos, Ionis, Alnylam, Novo Nordisk, Intellia, Bridgbio, Caelum, and Janssen. Dr Maurer has received consulting income from Eidos, Prothena, Ionis, Alnylam, Novo Nordisk, and Intellia; and has received institutional support in the form of clinical trial funding from Pfizer, Attralus, Ionis, Eidos, and Alnylam. Dr Trachtenberg has received consulting income from Alnylam, Eidos, and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.